Akorn (AKRX) Guides FY13 adj.-EPS Below Views, Revs In-Line; Reaffirms FY12
Tweet
Share
E-mailGet Alerts AKRX Hot Sheet
Price: $0.09 --0%
Financial Fact:
Research and development expenses: 10.62M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Research and development expenses: 10.62M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Akorn, Inc. (NASDAQ: AKRX), a niche pharmaceutical company, today provided full year 2013 financial guidance. The Company’s guidance excludes the impact from any products for which the Company has not yet received FDA approval. The Company will provide a more detailed update during its year-end 2012 conference call.
Total revs of $325 million to $335 million. The Street is at $330.7 million.
SG&A expenses of $51 million to $54 million.
Adjusted net income per share of 57 cents to 61 cents. The Street is at 66 cents.
CapEx of about $25 million.
Total revs of $325 million to $335 million. The Street is at $330.7 million.
SG&A expenses of $51 million to $54 million.
Adjusted net income per share of 57 cents to 61 cents. The Street is at 66 cents.
CapEx of about $25 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
Create E-mail Alert Related Categories
Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
